Capella Bioscience completes $15.5 million Series A financing
March 8, 2016 – LONDON. Capella Bioscience Ltd. announced today the close of a £11 million ($15.5 million), Series A financing round. The round was financed by Advent Life Sciences, Medicxi Ventures, and Osage University Partners. The new capital will support continued advancement of the company’s novel therapeutic antibody discovery programs towards clinical evaluation.
“We are delighted to receive this support from a strong and knowledgeable syndicate of investors to progress our development programs,” said Steve Holmes, COO of Capella. “In addition to providing significant financial resources, these experienced investors bring Capella a wealth of operational, medical, and industry expertise along with key relationships that will serve the company well during this important stage of growth and development.”
”Our investment to support the development of antibodies against a variety of high value targets at Capella is based on strong scientific research, combined with an experienced and capable drug development team,” commented Raj Parekh of Advent Life Sciences. “We look forward to working with the Company to translate its research into important new medicines.”
SOURCE Capella Bioscience, Ltd.